Forum Topic News
  • Conversation: EU green light for Cimzia to treat psoriasis

    • July 3, 2018 1:08 PM BST
      • Post(s)

      EU green light for Cimzia to treat psoriasis

      The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
      The approval makes Cimzia (certolizumab pegol), the first Fc-free, PEGylated anti-TNF treatment option for use in moderate-to-severe plaque psoriasis “and marks the entry of UCB into immuno-dermatology, where significant unmet need currently exists,” the firm noted.
      The CIMPASI-1 and -2 and CIMPACT trials confirmed the efficacy and safety of the drug in this setting.
      In all three trials, the drug showed “statistically significant improvements for all primary and co-primary endpoints compared to placebo at all tested doses”, and the clinical benefit was maintained through to week 48, according to the firm.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel